ies to bring products to market simply by claiming that they fal= under the PHS sec. 361 and 21 C.F.R. Part 1271 and then simply wait and see if the FDA ag=ees or disagrees. In meantime the product can be marketed. We believe many=products do meet these standards such as Osiris Grafix and RTIX's bone gr